CRUK
Cancer Research UK, Abcam Partner to Develop Custom Antibodies for Cancer Research
Abcam will develop custom protein-based reagents for
AstraZeneca, ArcherDx Partner on Minimal Residual Disease Monitoring for Lung Cancer Drug Trials
ArcherDx will develop sequencing-based circulating tumor DNA assays for use in AstraZeneca's recently launched Phase III MERMAID-1 trial of durvalumab (Imfinzi).
Genetic Alterations in Breast Cancer Influence Tumor Ecosystems
Researchers combined imaging mass spectrometry and genomic data to identify the cell types present in more than 480 breast cancer samples.
The number of technologies to be assessed is vast, and ranges from liquid biopsies and molecular imaging to immunohistochemistry and RNA-seq.
Lung Cancer Studies From TRACERx Consortium Explore How Tumor Cells Evolve
Researchers from the TRACERx consortium analyzed blood and tumor samples to tease out features of lung cancers that are more likely to recur.
Nov 30, 2018
Jan 26, 2016
Inivata Raises £31.5M in Series A Financing Round
Aug 21, 2015